Carcinoid Syndrome
📧 Sign up to get email alerts when something new happens for Carcinoid Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen [Phase 3]
A Phase 3 trial evaluating daily oral paltusotine for carcinoid syndrome is currently recruiting, with several carcinoid-related indications…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: CardioNETPOL National Registry of Carcinoid Heart Disease
This entry describes the CardioNETPOL national registry for carcinoid heart disease, collecting data on patients with carcinoid heart diseas…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors [EARLY_Phase 1]
This early-phase trial investigates a dual-energy CT scan to detect gastrointestinal carcinoid tumors, with status currently active but not …
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Fibrosis in Chronic and Delayed Myocardial Infarction
Clinical trial update indicating a study on fibrosis in chronic and delayed myocardial infarction is currently recruiting, with conditions i…
-
EMA approval · 2025-12-08EMA Authorised: Xermelo (telotristat etiprate) — SERB SAS
EMA authorised Xermelo (telotristat etiprate) for the treatment of carcinoid syndrome–related diarrhea in adults with neuroendocrine tumors,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome [Phase 2]
Phase 2 study of paltusotine in patients with carcinoid syndrome completed with results posted, detailing safety, pharmacokinetics, and dose…
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease [NA]
Clinical trial update for a transcatheter tricuspid valved stent graft in patients with carcinoid heart disease; the study is currently acti…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm [Phase 2]
Phase 2 AMT-PET monitoring study evaluating telotristat etiprate in participants with metastatic neuroendocrine neoplasms has completed and …
-
FDA approval · 2024-10-25FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Octreotide acetate submitted by Gland Pharma Limited.
-
FDA approval · 2024-09-27FDA Approved: BYNFEZIA PEN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved BYNFEZIA PEN (octreotide acetate) under an original NDA from Sun Pharmaceutical Industries. The product is an autoinjector pen …
-
CLINICAL_TRIALS trial_result · 2024-07-15Clinical Trial Update: Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
TerSera Therapeutics completed a real-world evidence study evaluating patient-reported outcomes for XERMELO (telotristat ethyl) in carcinoid…
-
FDA approval · 2024-07-09FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for octreotide acetate (ANDA 203765) submitted by Heritage Pharmaceuticals d/b/a Avet Pharmaceut…
-
FDA approval · 2024-07-09FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA granted supplemental approval for Octreotide Acetate from Heritage Pharmaceuticals (d/b/a Avet Pharmaceuticals Inc.).
-
FDA approval · 2023-12-05FDA Approved: OCTREOTIDE ACETATE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved OCTREOTIDE ACETATE as an original application, enabling a Teva-manufactured generic octreotide acetate.
-
FDA approval · 2023-06-30FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for octreotide acetate filed by Fresenius Kabi USA, LLC.
-
FDA approval · 2023-06-22FDA Approved: OCTREOTIDE ACETATE — Original Application (Gland Pharma Limited)
FDA approved OCTREOTIDE ACETATE from Gland Pharma Limited via an Original Application (ANDA 216839), establishing a generic version of octre…
-
FDA approval · 2023-06-13FDA Approved: OCTREOTIDE ACETATE — Original Application (Gland Pharma Limited)
FDA approved the original application for octreotide acetate, a generic product from Gland Pharma Limited. Octreotide acetate is indicated f…
-
FDA approval · 2023-02-21FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for octreotide acetate by Mylan Institutional LLC under ANDA 079198, granting a supplemental approva…
-
FDA approval · 2023-02-21FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application to Heritage Pharmaceuticals (Avet) for octreotide acetate, a generic product, under an ANDA.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs [Phase 2]
Phase 2 clinical trial update evaluating an amino acid–based medical food for diarrhea in neuroendocrine tumors, including carcinoid syndrom…
-
FDA approval · 2022-09-26FDA Approved: XERMELO — Supplemental Application (Lexicon Pharmaceuticals, Inc.)
The FDA approved a supplemental application for XERMELO (telotristat ethyl) from Lexicon Pharmaceuticals, Inc. This action updates the regul…
-
CLINICAL_TRIALS trial_result · 2020-08-04Clinical Trial Update: Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy [Phase 2]
Phase 2 clinical trial update investigating peptide receptor radiotargeted therapy for carcinoid heart disease and carcinoid syndrome/tumor.
-
FDA approval · 2020-02-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. (Avet Pharmaceuticals Inc.).
-
FDA approval · 2020-02-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under …
-
CLINICAL_TRIALS trial_result · 2019-10-25Clinical Trial Update: Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation [Phase 4]
Phase 4 trial update for Sandostatin (octreotide LAR) evaluating potential clinical improvement via receptor occupation optimization in neur…